Review

Probiotics in Autoimmune and Inflammatory Disorders

Yuying Liu, Jane J. Alookaran and J. Marc Rhoads *

The Department of Pediatrics, Division of Gastroenterology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX 77030, USA; Yuying.Liu@uth.tmc.edu (Y.L.); Jane.J.Alookaran@uth.tmc.edu (J.J.A.)

* Correspondence: J.Marc.Rhoads@uth.tmc.edu; Tel.: +1-713-500-7642

Received: 19 September 2018; Accepted: 15 October 2018; Published: 18 October 2018

Abstract: Probiotics have been used to ameliorate gastrointestinal symptoms since ancient times. Over the past 40 years, probiotics have been shown to impact the immune system, both in vivo and in vitro. This interaction is linked to gut microbes, their polysaccharide antigens, and key metabolites produced by these bacteria. At least four metabolic pathways have been implicated in mechanistic studies of probiotics, based on mechanistic studies in animal models. Microbial–immune system crosstalk has been linked to: short-chain fatty acid production and signaling, tryptophan metabolism and the activation of aryl hydrocarbon receptors, nucleoside signaling in the gut, and activation of the intestinal histamine-2 receptor. Several randomized controlled trials have now shown that microbial modification by probiotics may improve gastrointestinal symptoms and multiorgan inflammation in rheumatoid arthritis, ulcerative colitis, and multiple sclerosis. Future work will need to carefully assess safety issues, selection of optimal strains and combinations, and attempts to prolong the duration of colonization of beneficial microbes.

Keywords: lactobacilli; bifidobacilli; arthritis; inflammatory bowel; microbiome; metabolomics; aryl hydrocarbon reductase; adenosine; histamine; short-chain fatty acid

1. History of Probiotics

Health benefits of bacteria have been recognized throughout history. Fermented milk was consumed in the Middle East as early as 10,000 BC, followed by populations in Egypt (as evidenced by hieroglyphics), Greece, and Italy [1]. Around 8000 BC, Tibetan nomads living at altitudes >4000 m maintained good health despite the absence of fruits and vegetables in their diet, in part by consuming fermented yak milk and its products [2]. Only eight ounces of yak milk daily could provide >200 billion lactobacilli, mainly Lactobacillus fermentum (L. fermentum) and L. casei. Yak milk also has been found to have free-radical-scavenging and anti-inflammatory properties. In ancient Greece and Rome around 400 BC, a condiment called garum, derived from fish intestines, which was (and still is) fermented for 12–18 months in clay pots, was consumed daily, with powerful antioxidant properties and reported health benefits [3]. Nomadic Turks used “yogurmak” to treat diarrhea, cramps, and sunburned skin, as evidenced by writings in the 11th century; and later, Genghis Khan, the great Mogul conqueror, fed his army yogurt, because it reportedly “instilled bravery in them” [4].

In 1905, Elie Metchnikoff of Russia probed the question of why Bulgarians lived so long. He concluded that their longevity was related to the heavy consumption of fermented yogurt, subsequently showing that a bacillus could be grown from the yogurt, which was identical to a bacillus found in their stools, later called L. bulgaricus [5]. At the same time, Henry Tissler of Paris isolated from an infant a y-shaped organism that he called Bifidobacterium. This bacterium was able to displace pathogenic bacteria in vitro. Healthy infants were colonized with the Bifidobacterium,
whereas less healthy infants did not harbor the organism. Later, in World War I, many soldiers were dying of diarrheal disease, and the German scientist Alfred Nissle isolated a strain of *E. coli* from a soldier that had *Shigella* in the stool but did not develop diarrhea [6]. The species, which he called “antagonistically strong”, was appropriately called *E. coli* Nissle 1917 and is still used as a probiotic today (called “Mutaflor”).

1.1. Recognized Benefits in the 1900s

The term probiotic was introduced in 1953 by the German Werner Kollath to mean “active substances essential for a healthy life” [5]. In the 1940s, most research focused on culturing pathogenic bacteria and developing antimicrobial therapies. In line with this approach, after the 1950s, there was great interest in identifying probiotics that provided colonization resistance to pathogens, and research began to focus on lactobacilli and bifidobacilli to combat diarrheal disease. This research focused on the role of probiotics and “gut health” and resulted in convincing evidence that probiotics can prevent and treat infections causing diarrhea (viral, salmonellosis, shigellosis, cholera) [7] and also facilitate peptic ulcer healing [1].

1.2. Expanded Role in Infants and in Patients with Gastrointestinal Disorders (2000–Present)

Between 2000 and 2017, there was an explosion of interest in probiotics, with an annual number of randomized controlled trials (RCTs) ranging between 144 and 194; in 2017, there were also 49 meta-analyses. Internationally recognized investigators have spent decades of their lives developing the field of probiotic research.

Four significant conditions will be mentioned that have consistently been shown to respond to probiotics in humans in meta-analysis.

*Necrotizing enterocolitis (NEC).* Research was emerging around 2000 showing that probiotics could prevent necrotizing enterocolitis, a devastating disease of premature infants often resulting in bowel resection and short bowel syndrome. The first meta-analysis by Alfaleh and Bassler was published in 2008, showing benefit of probiotics in nine trials [8]. By 2017, more than 23 studies in 7325 infants showed that probiotics reduce the risk of developing NEC. This most recent meta-analysis by Thomas et al. showed that the risk of developing NEC was 3.9% if given probiotics and 6.6% if untreated with probiotics (relative risk of 0.57, 95% confidence interval (CI) 0.43–0.74, *p* < 0.0001) [9]. The problem with these studies was that there were many probiotics studied, and sometimes multiple-strain probiotics were tested; therefore, the optimal choice was not evident. One meta-analysis found that the benefit was restricted to multiple-strain probiotics and to lactobacilli [10], while another meta-analysis (oppositely) found that the benefit pertained only to bifidobacilli and multiple-strain probiotics [11]. Both groups found that the yeast *Saccharomyces* was ineffective.

Of concern, the premature population is at high risk for septicemia, and therefore safety concerns have until recently led to the U.S. Food and Drug Administration (FDA)'s caution in approving any probiotic RCTs in the United States. Paradoxically, probiotics have been consistently shown to reduce the risk of late-onset septicemia in breast-fed premature infants [12]. Simultaneously with these clinical trials, animal research has confirmed efficacy of probiotics in preventing NEC, while also establishing possible mechanisms. Dvorak’s group showed that *Bifidobacterium bifidum* stabilized the gut barrier via tight junction modification during experimental NEC [13]. Hackam’s group showed that NEC is mediated by inflammatory signaling via the epithelial cell pattern recognition receptor Toll-like receptor-4 (TLR4). TLR4 recognizes bacterial lipopolysaccharide and is expressed on gut epithelial cells and immune cells, such as T cells. Hackam et al. showed that the mitigating effects of *L. rhamnosus* HN001 are mediated by anti-inflammatory signaling via TLR9 [14]. Our group showed that protective effects of the probiotic *Lactobacillus reuteri* DSM 17938 (*L. reuteri* 17938) in a mouse model of NEC are mediated by a different Toll-like receptor, TLR2 [15], and its administration to newborn mice and rat pups results in an enhancement of local and peripheral levels of anti-inflammatory regulatory T cells (Tregs) [16].
Irritable bowel syndrome (IBS). IBS is defined as recurrent abdominal pain at least one day weekly for >3 months, which is: (a) related to defecation; (b) associated with a change in stool form; or (c) related to a change in stool [17]. Subjects with IBS have been found to harbor an altered fecal microbial population, with a shift toward reduced microbial diversity and reduced butyrate-producing bacteria. In addition, Pozuelo et al. showed that adults with IBS-C (constipation-predominant) differ from control individuals without IBS and from those with IBS-D (diarrhea-predominant IBS) [18]. This finding was consistent with many studies of probiotics for patients with IBS. Meta-analyses have shown considerable heterogeneity, largely related to various definitions of symptom severity in IBS and quality-of-life indicators. However, most meta-analyses have shown efficacy of probiotics in treating IBS [19]. The most recent meta-analyses by Ford et al. [19] and Zhang et al. [20] showed a decrease in global IBS symptoms of ~2-fold and an improvement in quality of life. Many studies showed improvement in bloating and flatulence in those with IBS. Different probiotics have been studied, and the meta-analyses have shown considerable heterogeneity. Therefore, the role of probiotics in IBS is best described as “evolving but promising.”

Infant colic. Babies who cry and fuss for more than 3 h daily have colic. The condition generally starts at 3 weeks of age, occurs on more than 3 days/week, and resolves after 3 months of age (hence the “rule of threes” [21]. Infant colic previously was felt to be unresponsive to any treatment. Microbial dysbiosis began to be linked to this condition and was confirmed by several groups [22–24], and it was linked to gut inflammation [25]. Therefore, colic might represent a condition for which probiotic treatment would be useful. Several meta-analyses have shown that the probiotic *L. reuteri*, isolated from a Peruvian mother’s breast milk, reduces crying time and irritability in this condition [26–28].

Respiratory infections. Recently, lactobacillus- and bifidobacillus-containing probiotics were found to improve outcomes in acute infectious diseases outside of the gastrointestinal tract, such as upper and lower respiratory tract illnesses in infants and college students [29–32]. In one moderately large multicenter study in Italy, the addition of fermenting *L. paracasei* to milk or rice milk resulted in reduced episodes of gastroenteritis, rhinitis, otitis, laryngitis, and tracheitis [33]. This finding suggested that the benefits to the host extend beyond local interactions in the intestinal tract between the gut organisms, enterocytes, and the immune system, perhaps involving microbial metabolites and/or migrating dendritic cells that reach distant locations such as the spleen and lymph nodes. Of additional benefit, probiotics stimulate immunoglobulin A (IgA) secretion in the respiratory epithelium in animal models [34]. Currently, several over-the-counter products espouse the benefits of probiotics in treating common upper respiratory ailments.

2. Effects of Probiotics in High-Risk Populations with Immune Dysregulation and Autoimmune Diseases

In both animal trials and human trials, probiotics have been investigated to determine potential beneficial effects in the prevention and treatment of a wide variety of systemic conditions. These conditions include inflammatory and autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, and hepatic encephalopathy. Advantages of probiotics include the regulation of immune system function, which is often dependent on the strain of probiotic bacteria. Some strains have demonstrated stimulation of the immune response, thereby being beneficial to patients suffering from immunodeficiency [35]. Other strains have been shown to inhibit the immune response, thereby being beneficial for patients suffering from conditions with immune activation such as rheumatoid arthritis (RA) [36,37].

Rheumatoid arthritis (RA). Rheumatoid arthritis is a systemic autoimmune disease characterized by autoantibody formation leading to the chronic inflammation of multiple joints. RA is also known to affect other internal organs, including the lungs, heart, and kidneys [38]. Triggers leading to RA include human leukocyte antigen (HLA) gene interaction and environmental factors. These environmental factors include smoking, infection, and recently, dysbiosis [36,39,40]. Early animal models have consistently demonstrated an interaction between the gut microbiota and local/systemic immunity as
well as activation of joint inflammation [41]. In earlier probiotic studies, investigators were not able to show a significant difference in activity of RA with the use of probiotics [42], but in a more recent study, Zamani et al. reported that probiotic supplementation resulted in improved disease activity scores (looking at 28 joints) in patients with RA, compared with placebo [43]. A study by Chen et al. evaluated the gut microbiota profile in 40 patients with RA and 32 healthy controls. They found decreased gut microbial diversity in RA compared to controls, which additionally correlated with disease duration and with levels of serum rheumatoid factor [44]. Alipour et al. showed that L. casei 01 supplementation decreased serum high-sensitivity C-reactive protein (hs-CRP) levels, reduced tender and swollen joint counts, and improved global health (GH) score ($p < 0.05$). A significant difference was also observed between the two groups with respect to circulating levels of interleukin (IL)-10, IL-12, and tumor necrosis factor (TNF)-α, in favor of the probiotic group [45].

In a recent meta-analysis, Mohammed et al. showed that the proinflammatory cytokine IL-6 was significantly lower in rheumatoid arthritis volunteers treated with probiotics compared to their placebo-treated controls. However, this study did not show an overall difference in clinical symptoms between the probiotic and placebo groups [37]. Another study, by Liu et al., aimed to investigate the human fecal lactobacillus community and its relationship to RA. In comparing quantitative polymerase chain reaction (PCR) in fecal samples of 15 RA patients and 15 healthy controls, the authors reported increased absolute numbers of Lactobacillus salivarius, Lactobacillus iners, and Lactobacillus remini in untreated RA patients and suggested a potential relationship between the lactobacillus community and development of RA [46]. Thus, evolving evidence suggests a relationship between altered intestinal microbiota and rheumatoid arthritis, and we anticipate that further studies will be needed to delineate the microbiota profiles which might contribute to RA and the potential for treatment with adjuvant probiotics.

Systemic lupus erythematosus (SLE). SLE is an autoimmune disease involving multiple organs, including the skin, joints, kidneys, and central nervous system and is characterized by the formation of high levels of antibodies against double-stranded DNA. SLE is influenced by genetic and environmental factors and is characterized by immune intolerance to self-antigens [47]. In a classic hypothesis regarding the etiology of lupus in 1964, Kingsley Stevens pointed out that polysaccharide-containing antigens were 60-fold more effective stimulators of plasma cell proliferation and antibody formation than were the protein antigens present in vaccines [48]. He went on to propose that “the causative agent in SLE” is a bacterial polysaccharide, which must be present in the oropharynx, vagina, or gut. In humans with SLE, elevated interferon-gamma has been found to be proportional to the fecal fimbicutes/bacteroides level, giving credence to Stevens’ hypothesis [49]. In this study, several strains of probiotics were helpful in the modulation of excessive inflammatory responses in vitro. Both experimental and clinical trials have revealed that selective strains of probiotics (B. bifidum, Ruminococcus obeum, Blautia coccoides, and L. casei strain Shirota) can reduce inflammation and restore tolerance in SLE animal models [50]. There are several mouse models of SLE; for example, the MRL/lpr mouse that spontaneously develops nephritis. MRL/lpr mice suffer from endotoxemia and increased gut paracellular permeability [51]. Using MRL/lpr mice, researchers found that combinations of lactobacilli or L. reuteri alone, when given enterally, skewed Treg–Th17 balance toward Treg cell dominance, reduced endotoxemia, reduced levels of double-stranded DNA-reactive IgG, improved proteinuria, and better survival. These results were associated with a change in gut microbiota, with expansion of Clostridiales, Lactobacilli, and Desulfovibrionales. In the NZB/W F1 mouse, systemic lupus-like inflammation is characterized by oxidative stress and reduced levels of circulating regulatory (anti-inflammatory) Tregs [52]. Treatment with L. reuteri GMNL-263 reduced levels of cytokines and restored Tregs in this model as well.

At this time, we are unaware of any randomized controlled trials of a probiotic for patients with lupus, but there is evidence that the gastrointestinal tract may be an avenue for disease modification. In vitro, probiotic lactobacilli when cultured with immature dendritic cells from lupus patients reduce the expression of costimulatory molecules and increase levels of interleukin-10 and indoleamine...
2,3-dioxygenase (anti-inflammatory molecules), suggesting that they could promote immune tolerance [53]. A pilot study by Frech et al. in a related autoimmune disorder, progressive systemic sclerosis, suggested that probiotics significantly improved esophageal reflux, distention and bloating, and total gastrointestinal symptom scales [54].

_inflammatory bowel disease (IBD)._ IBD, including ulcerative colitis (UC) and Crohn’s disease (CD), is characterized by chronic inflammation in the gastrointestinal tract influenced by several factors, including genetics, epigenetics, gut microbiota, and the host immune system [55]. There have been many RCTs evaluating the effects of probiotics in IBD, associated with ample evidence suggesting that altered gut microbiota contribute to the initiation and progression of IBD. It has been well established that VSL #3, an eight-strain probiotic which includes lactobacilli, bifidobacilli, and _Streptococcus thermophilus_, is effective in UC; however, this and other probiotics were not effective in CD [56]. In 2017, Derwa et al. showed VSL #3 to be effective in inducing remission in active UC and suggested that probiotics may be as effective as 5-ASAs in preventing relapse of quiescent UC [57,58]. In a recent meta-analysis of 27 trials, Ganji-Arejanaki et al. confirmed that VSL #3 was effective in UC and showed that probiotics _S. boulardii_, Lactobacilli (_L. rhamnosus_, _L. johnsonii_), and VSL #3 were effective in patients with CD who also used corticosteroids [59]. The authors suggested that the use of VSL #3 and _Lactobacillus johnsonii_ after surgery for CD might be efficacious if the duration of treatment under study were longer. Ganji-Arejanaki et al. additionally concluded that in children aged 2–21 years with IBD (both CD and UC), lactobacilli (_L. reuteri_ ATCC 55730, _L. rhamnosus_ strain GG, and VSL #3) confer a significant advantage. The role of probiotics in patients with persistent gastrointestinal complaints when inflammation cannot be demonstrated remains to be determined. Overall, in inflammatory bowel disease, probiotics appear to be safe and promising, but not proven as adjuvants to standard therapy [57].

_Multiple sclerosis (MS)._ MS is a chronic relapsing or progressive disease of the brain and spinal cord characterized by onset in early to middle adulthood with relapsing neurologic deterioration. Many individuals with MS develop sensory loss, weakness, visual difficulties, severe fatigue, and paresthesias. Key pathological features of MS include axonal loss, demyelination, gliosis, and a progressive inflammatory reaction of the brain and spinal cord [60,61]. During the course of MS, activated autoreactive T cells have been proposed to differentiate into interferon-γ-producing T helper 1 (T_H1) cells and/or interleukin (IL)-17-producing T_H17 cells, which are distributed throughout the central nervous system and spinal cord [62]. Growing evidence from both rodent and human studies suggests that microbiota within the intestine contribute to the pathogenesis in this disease [63–66]. In a rodent model of MS called experimental autoimmune encephalomyelitis (EAE), two studies showed that alteration of the gut microbiota by oral antibiotic administration reduced the severity of EAE [67,68]. Human studies of MS patients recently showed that the relative abundance of the families _Prevotella_ and _Lactobacilli_ are decreased compared to healthy controls [64,65]. Similarly, we found in the EAE model that there was evidence for fecal microbial dysbiosis and reduction of _Prevotella_ during the disease. We also found that _L. reuteri_ improved clinical severity of EAE, shifted the microbial beta diversity, and reduced Th1 and Th17 cytokine levels in the serum and gut [69]. There is one human study suggesting that _L. reuteri_ improves symptoms and quality of life in human MS [70]. Thus, evidence from MS in humans and mice provides further evidence of a strong connection between the human brain and gut, with microbes and their products being key mediators of disease severity, while beneficial microbes represent key candidates for disease modification.

3. Mechanism of Action of Probiotics

Probiotics have been found to affect every compartment of the gut, including the luminal microbiome, the mucus barrier, the microbe- and cell-free “kill zone” of the epithelium, the lymphocyte- and plasma cell-rich lamina propria, the vascular and neural elements of the lamina propria, the underlying smooth muscles which control motility, and the mesenteric lymph nodes that communicate with the systemic immune system. Probiotic-modulated local and systemic metabolites
have been identified which may modify autoimmune diseases and the mechanisms are summarized in Figure 1.

**Figure 1.** Critical metabolites produced by probiotics which have anti-inflammatory functions. SCFAs (acetate, butyrate, and propionate) produced by bifidobacilli, lactobacilli, and commensals bind and activate receptors (FFAR2, FFAR3, or GPR109a) on intestinal epithelial cells to inhibit the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to prevent inflammation. They also inhibit histone deacetylases to promote accumulation of Tregs and may release GLP1/PYY to act on the enteric nervous system and the CNS to affect energy homeostasis and gut motility. SCFAs also induce tolerogenic DC, which educate naïve CD4+ T cells to differentiate into Tregs. These actions inhibit cytokine production by neutrophils and macrophages via interaction with receptors. Dietary tryptophan and probiotic-produced indole derivatives interact with AhR expressed on immune cells to produce anti-inflammatory effects. *L. reuteri* 17938 promotes adenosine generation, most likely by an ectonuclease present on the probiotic itself and on intestinal epithelial cells. Adenosine and its derivative inosine interact with adenosine receptor-2A located on T cells to promote Treg functions and inhibit inflammatory Th1 and Th17 subsets. Histamine produced by *L. reuteri* 6475 interacts with H2 presented on intestinal epithelial cells and macrophages to reduce levels of proinflammatory cytokines (TNF-α, MCP-1, and IL-12). In summary, the critical metabolites produced by probiotics generate anti-inflammatory effects during diseases. Abbreviations: SCFAs: short-chain fatty acids; FFARs: free fatty acid receptors; GPRs: G-binding protein receptors; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; GLP1: glucagon-like protein-1; PYY: peptide tyrosine tyrosine; CNS: central nervous system; AhR: aryl hydrocarbon receptor; Th1 and Th17: T helper cells; H2: histamine receptor 2; TNF-α: tumor necrosis factor alpha; MCP-1: monocyte chemoattractant protein-1; IL-12: interleukin-12 (illustration by Yuying Liu).

**Short-chain fatty acid (SCFA) production in the colon.** SCFAs, specifically acetate, propionate, and butyrate, are produced by commensal bacteria (such as *Facecalibacterium praunsitizii*, *Eubacterium rectale*, *Eubacterium hallii*, and *Ruminococcus bromii*) and by many probiotics. Lactobacilli were once thought to produce SCFAs and pyruvate by fermentation of carbohydrates and heterofermentative processes [71]; however, they do not produce SCFAs directly. As members of a trophic chain leading to butyrate production, they produce mainly lactate [72]. Lactate is further metabolized by strictly anaerobic butyrate producers from the Firmicutes phylum (which includes *Lachnospiraceae*, *Ruminococcaceae*, *Erysipelotrichaceae*, and *Clostridiaceae*). Bifidobacteria use fermentation to produce SCFAs, mainly acetate and formate, during growth when carbohydrates are limited. Bifidobacteria alternatively produce acetate and lactate when carbohydrates are in excess [73].
Various dietary carbohydrates (called prebiotics) can selectively stimulate microbial growth and metabolic activity. A combination of probiotics and prebiotics (called a synbiotic) is powerfully able to shift the predominant bacteria and production of SCFAs. For examples, *L. rhamnosus GG* (LGG) with a mixture of prebiotics produces SCFAs. *Lactobacillus acidophilus* CRL 1014 was also recently shown to increase SCFAs (acetate/butyrate/propionate) when studied in a reactor called SHIME (Simulator of Human Microbial Ecosystem) [74]. Bifidobacteria such as *B. longum SP 07/03* and *B. bifidum MF 20/5* produce and release propionate and acetate, but not butyrate [75].

SCFAs may have beneficial effects on gut health through various mechanisms. SCFAs play an important role in maintaining metabolic homeostasis in colonocytes, and they protect colonocytes from external harm. SCFAs, especially butyrate, confer protection against the development of colorectal cancer (CRC) [76,77]. Butyrate promotes colon motility, reduces inflammation, induces apoptosis by inhibition of histone deacetylation, and inhibits tumor cell progression. Evidence points toward SCFA receptors in the colon, which includes both free fatty acid receptors (FFARs) and G-protein-coupled receptors (GPRs). FFAR3 (GPR41) and FFAR2 (GPR43) on colonocytes control motility [78]. SCFAs are able to bind and activate FFAR2 and/or FFAR3 located on intestinal epithelia, inducing glucagon-like protein-1 (GLP-1) and peptide tyrosine tyrosine (PYY) release into the basolateral milieu. Released GLP-1 and PYY activate enteric or primary afferent neurons in pelvic and vagal networks. Neural information travels to the central nervous system (CNS), affecting host metabolic energy expenditure [79]. SCFAs reduce neutrophil cytokine production [80], while reducing macrophage nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling [81], resulting in anti-inflammatory actions. Most importantly, butyrate has the ability to induce the differentiation of Tregs, which control intestinal inflammation [82]. However, the understanding of the underlying molecular mechanisms remains incomplete, mainly due to the lack of data on actual uptake fluxes of SCFAs under different conditions, i.e., with different dietary substrates, microbiota, and disease models. Most studies report concentrations of metabolites or transcript levels, but these do not necessarily reflect SCFA flux changes [75].

Under certain circumstances, treatment with probiotic lactobacilli could yield metabolites in the SCFA pathway that may be harmful. In the setting of short bowel syndrome, infants have been reported to develop D-lactic acidosis (which is not made by human cells) [83], because of the low abundance of the anaerobic microbiota capable of lactate utilization [84] and a dominance of lactobacilli in the feces [85].

Tryptophan metabolism–aryl hydrocarbon receptor activation. L-Tryptophan (Trp) plays crucial roles in the balance between intestinal immune tolerance and activation [86]. Recent studies have underscored the changes in the gut microbiota that modulate the host immune system by modulating Trp metabolism. Trp metabolites include host-derived Trp metabolites, such as kynurenines, serotonin, and melatonin, but also bacterially produced Trp metabolites, including indole, indolic acid, skatole, and tryptamine [87]. Trp metabolites are ligands of the aryl hydrocarbon receptor (AhR) [88]. AhR is a cytosolic ligand-activated transcription factor in dendritic cells and T cells. AhR plays a critical role in maintaining gut immune tolerance and barrier function, as evidenced by the finding that AhR-null mice exhibit severe symptoms and mortality in animal models of dextran sodium sulfate (DSS)-induced colitis [89]. AhR−/− mice are more susceptible to intestinal challenge with toxins [90] and pathogens [91]. Studies have identified a critical mechanism of AhR in immune tolerance involving anti-inflammatory IL-22 production, which tolerizes intraepithelial T lymphocytes and innate lymphoid cells (ILCs) [92]. Host and bacterial Trp metabolites stimulate AhR and AhR-dependent gene expression, including IL-6, IL-22, prostaglandin G/H synthase 2 (PTGS2), vascular endothelial growth factor A (VEGFA), cytochrome P450 1A1 (CYP1A1), and mucin 2 (Muc2) in the intestine. These products individually and additively modulate intestinal homeostasis [87].

The effects of indolic acid derivatives produced from Trp by gut bacteria and probiotics have earned recognition as major metabolic products in this process. Metabolites such as indole-3-acetic acid (IAA), indole-3-aldehyde (IAId), indole acryloyl glycine (IAcrGly), indole lactic
acid (ILA), indole acrylic acid (IAcrA), and indolyl propionic acid (IPA) all can impact intestinal homeostasis. For example, Clostridium sporogenes can convert Trp into IPA, which protects mice from DSS-induced colitis [93]. IPA significantly enhances anti-inflammatory cytokine IL-10 production after lipopolysaccharide (LPS) stimulation and reduces TNF-alpha production. The probiotic Bifidobacteria infantis, when given enterally, attenuates proinflammatory immune responses by elevating plasma Trp and kynurenic acid levels in rats [94]. The probiotic Lactobacillus reuteri, in the presence of luminal Trp, produces IAld, which is able to activate ILC3 cells to produce IL-22 via AhR, contributing to antifungal resistance and mucosal protection from inflammation [95]. In summary, as a therapeutic strategy, probiotic treatment in combination with Trp metabolism can alter the intestinal microbiota, increase the generation of AhR ligands, and ultimately protect the host from intestinal inflammation.

**TGF-β and Tregs.** Transforming growth factor-beta (TGF-β) is a multifunctional polypeptide with profound regulatory effects which affect many developmental and physiological processes. TGF-β in the intestinal mucosa is a key immunoregulatory molecule, shown to induce Tregs and to promote B-cell IgA production. One TGF-β signaling pathway activates the transcriptional factors SMAD2 and SMAD3 [96]. SMAD3 is a crucial transcription factor enhancing Foxp3 expression in Tregs. TGF-β induces Foxp3 gene transcription in thymic Treg precursors, and also converts naïve T cells into inducible Treg (iTregs), while protecting Tregs from apoptosis [97]. Probiotic bacteria have been shown to generate a Foxp3+ Treg response in the small intestine. Our study of experimental NEC models demonstrated that orally feeding L. reuteri 17938 increases the frequency of Foxp3+ Tregs in the intestinal mucosa to prevent the development of NEC [16,98]. Lactobacillus gasseri SBT2055 induces TGF-β expression in dendritic cells and activates TLR2 signaling to produce IgA in the small intestine [99]. Probiotic VSL #3-induced TGF-β also ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of Tregs in the gut mucosa [100]. The administration of B. breve to preterm infants also can upregulate TGF-β1 signaling and may possibly be beneficial in attenuating inflammatory and allergic reactions in infants [101]. In the setting of infectious enteritis, L. acidophilus attenuates Salmonella typhimurium-induced gut inflammation via TGF-β1 signaling [102].

**Nucleoside (adenosine) signaling.** We have identified a novel mechanism of L. reuteri 17938 in regulating multiorgan inflammation. L. reuteri modifies the microbiota–adenosine-inosine receptor 2A (A2A) axis, which in turn inhibits T_{H1} and T_{H2} cell differentiation to reduce inflammation in the liver, lungs, gut, and skin [103,104]. This mechanism was identified in the “scurfy” mouse model, in which genetic Treg deficiency induces autoimmune total body inflammation. Foxp3+ Treg cell deficiency in these mice results in gut microbial dysbiosis and autoimmunity over their entire lifespan. A severe autoimmune disease named IPEX syndrome (immunodysregulation, polyendocrinopathy, enteropathy, with X-linked inheritance) is the parallel syndrome in humans [105]. Remodeling gut microbiota with L. reuteri 17938 markedly prolonged survival and reduced multiorgan inflammation in scurfy mice. We found that L. reuteri 17938 changed the metabolomic profile disrupted by Treg deficiency; and the predominant change was to restore serum levels of the purine metabolite inosine, alongside the downstream products xanthine and hypoxanthine. One of the key mechanisms of Tregs is to control inflammatory effector T cells (Tem). Tems include T_{H1}, T_{H2}, and T_{H17} subsets of T cells; these proinflammatory families of T cells are controlled via the interaction of adenosine (produced by Tregs) and the receptor A2A, which is highly expressed on T cells. In the absence of Tregs, the adenosine metabolite inosine at high doses may replace the effect of adenosine to interact with the A2A receptor and inhibit T_{H} cell differentiation. When we fed inosine itself to Treg-deficient scurfy mice, we observed that inosine prolonged lifespan and inhibited multiorgan inflammation by reducing T_{H1}/T_{H2} cells and their associated cytokines. Mechanically, the inhibition by L. reuteri and inosine of the differentiation of T_{H1} and T_{H2} cells depended on the A2A receptor, which was confirmed by using an A2A antagonist to block A2A receptors [103] and by genetic knockout of the A2A receptor in sf mice [104].
Histamine signaling. The tolerogenic effects of lactobacilli are very strain- and metabolite-dependent. For example, a *L. rhamnosus* strain that secretes low levels of histamine is immunosuppressive \[106,107\], whereas a *L. saerimneri* strain secreting high histamine levels induces gut inflammation \[108\]. In a series of studies, *L. reuteri* ATCC PTA 6475 (*L. reuteri* 6475) was found to differ from the sister strain *L. reuteri* 17938, in that *L. reuteri* 6475 makes histamine. Histamine is produced by *L. reuteri* 6475 via the action of histidine decarboxylase (HDC). Its production of histamine suppresses TNF-α synthesis in vitro \[109\]. Gao et al. showed that *L. reuteri* 6475 has anti-inflammatory effects in the trinitrobenzoate (TNBS) model of colitis via a mechanism dependent on intestinal histamine-2 receptor signaling \[110\]. A mutant *L. reuteri* 6475 strain lacking HDC did not suppress TNBS-induced colitis in mice; furthermore, the anti-inflammatory effect of *L. reuteri* 6475 was dependent on the histamine H-2 receptor on intestinal cells \[111\]. This HDC-dependent gene effect may be of relevance to colorectal carcinoma, which, interestingly, is more prevalent in humans deficient in HDC. As a proof of concept, *L. reuteri* 6475, when administered in a Hdc<sup>−/−</sup> mouse model of colon cancer, suppressed tumor size and number, presumably by its synthesis of histamine \[111\].

4. “Polarization” within the Medical Community Regarding the Use of Probiotics

The medical community has not yet endorsed the use of probiotics. In fact, the U.S. Food and Drug Administration has not yet approved any probiotics for preventing or treating any health problem. Despite the numerous evidence-based reviews and meta-analyses cited herein, there are legitimate reasons for caution. Many of the meta-analyses suffer from the practice of lumping together different probiotics which may have widely different mechanisms of action. Some experts have warned that the rapid growth in the marketing of probiotics may have outpaced scientific research for many of their proposed uses and benefits \[112\]. More concerning is that there have been rare reports of bacteremia with cultures positive for the probiotic administered, leading to probiotic-associated endocarditis and even death. One notable case involved an infant who developed invasive mucormycosis, leading to intestinal perforation and death, resulting from a probiotic (ABD-Dophilus) which was contaminated with a fungus, *Rhizopus oryzae* \[113\]. However, overall, probiotic groups compared with matched placebo-treated controls have often shown a reduction in sepsis rates, as shown in preterm infants \[114,115\] and in adults following gastrointestinal surgery \[116\].

There are other concerns among skeptics.

Numerical skepticism. The argument is sometimes raised, “How can 1–100 billion colony-forming units (CFUs) of a probiotic outweigh the effects of 10–75 trillion commensals in the gut?”, noting a 1:1000 ratio of probiotic to commensal bacteria \[117\]. This numerical consideration is based on an assumption that a probiotic would need to establish itself (colonize) and differentiate in the large intestine. Consider the following: An infective dose of *E. coli* 0157:H7 of only 50 CFUs is sufficient to cause a potentially lethal bloody diarrhea in humans, leading to the hemolytic uremic syndrome \[118\]. It is actually remarkable that the previously mentioned body of research does show significant effects of probiotics in light of the sheer numbers of normal commensal microorganisms. However, the meta-analyses above show evidence of probiotic efficacy without significant colonic colonization. Most studies can show limited recovery of probiotics in the stool \[119\], but the number of colony-forming units (CFUs) for *L. reuteri* are on the order of 1:1000 of the dose administered and for *L. rhamnosus* GG are only 1:10,000 of the dose administered \[120\]. Another study showed fecal recovery of orally administered *L. fermentum* probiotic, but as in most studies, there was only a low level of the probiotic in the stool \[121\]. We have not consistently been able to identify by PCR significant numbers of probiotic in the stools—even while patients are actively on treatment \[122,123\]. Nevertheless, in our studies of *L. reuteri*, we have consistently found significant evidence of recognition by the host of the probiotic; for example, a mild elevation in the fecal level of the antimicrobial calprotectin (within the normal range) \[124\], a shift in microbial community composition, and an increase in circulating neutrophil count in infants with colic \[125\]. We believe a possible explanation lies in the observation...
that most lactobacilli and bifidobacilli are primarily small bowel colonizers, where they exert their immunologic effects.

Publication bias. It is generally recognized that clinical trials with negative findings are hard to publish. For this reason, meta-analyses will often contain a funnel plot, an asymmetry of which is a way of determining publication bias [126]. Funnel plots for probiotic studies have generally shown no publication bias for probiotics in most of the conditions described, such as NEC prevention [127], IBS improvement [128], H. pylori eradication [129], and amelioration of infant colic [130]. Nevertheless, there is much work to do in identifying optimal strains and using meta-analysis to prove the effect size of the disease (which in some cases may be significant, but only minor).

Generalizability of findings. Some have argued that a probiotic may be effective only in a well-defined, narrow population. For example, is there greater efficacy in children versus adults? Children less than 3–6 years old have an incompletely developed microbiome and may be more responsive to microbial manipulation. The strongest effect size for probiotics has been shown in pediatric studies; for example, the effect of probiotics in reducing the incidence of NEC (in the latest systematic reviews, the relative risk (RR) was 0.55, 95% confidence interval (CI) 0.43 to 0.70) or in shortening the course of acute infectious diarrhea (0.67 days, 95% CI –0.95 to –0.38) [131].

Safety in immunodeficient states. Finally, there is concern about giving chemotherapeutic agents or immunomodulators along with live microorganisms to patients who are immunocompromised. Children and adults with autoimmune diseases, such as lupus, ulcerative colitis, and rheumatoid arthritis, are often on immunosuppressive medications, biologics, or corticosteroids. Is it safe to give probiotics to these individuals? Our opinion is that it is safe and indicated. In fact, may the question may be better phrased, “Is it safer to give probiotics than not to withhold them?”, in view of the deleterious effects of patient exposure to multiple systemic antibiotics, resulting changes in microbiome, and alterations in barrier function of intestinal and other epithelial surfaces in these patients. Certainly, clinicians are quick to administer antimicrobial and/or antiviral agents to these individuals. There are numerous RCTs in the literature describing adults and children with cancer and immunodeficiency who have been treated with probiotics or placebo [132–135]. The most comprehensive review to date examined safety in immunocompromised adults using common terminology adverse event reporting. There were 57 studies in 4914 individuals, 2506 of whom received a probiotic or synbiotic. These included critically ill “intensive care unit” subjects, those with cancer, human immunodeficiency virus (HIV)-infected individuals, and those with arthritis, inflammatory bowel disease, or recent gastrointestinal surgery [136]. The authors concluded that probiotics were safe and, overall, associated with fewer adverse events compared to the control group. However, there were flaws in precise reporting in most of the cited studies. That report was in 2014, and it is likely that there will be upcoming reports and systematic reviews of probiotics in immunocompromised individuals.

5. The Future of Probiotics

Henri Poincare said in The Foundations of Science that, “It is far better to foresee even without certainty than not to foresee at all.”. Based on the collective evidence, the authors suggest the following events are likely to take place in the near future.

Probiotics are likely to be used in autoimmune diseases as a component of various treatment regimens. One size will not fit all. The choice of optimal probiotic or multispecies strains will evolve for each disease entity studied.

The present “third-party” insurance reimbursement problem will change. Currently, insurance plans in the U.S. cover antibiotics, but not probiotics; but (as discussed) a body of evidence is evolving to support that clinical outcomes will be improved with probiotics. Once safety issues
in vulnerable populations are adequately addressed by properly controlled and regulated trials, we expect widespread use in children and adults with autoimmune disorders and (we hope for) coverage by insurance plans.

Quality improvement efforts by medical institutions will likely reward treatments with the best outcome. An example of this is the protocol for treatment of infants admitted to hospital with diarrheal dehydration at Cincinnati Children’s Hospital. An international working group selected care protocols for children with acute diarrhea, using systematic reviews, Delphi methodology, and external peer review. They decided that oral rehydration and probiotics were the only treatments recommended for infants presenting with acute diarrhea [137]. Investigators placed in the electronic order set an entry for the administration of Lactobacillus rhamnosus GG. After implementation of this initiative, the prescribing of this probiotic increased from 1% to 100% [138]. However, a retrospective study of 145 U.S. hospitals assessing ~1,900,000 hospital discharges showed that only in 2.6% of all hospitalizations were probiotics administered [139].

Novel delivery systems will facilitate probiotic delivery and efficacy. “Designer probiotics” is a term that has been given to probiotics with genetic engineering to facilitate delivery to the small intestine, enhance competitiveness within the gastrointestinal tract, and improve outcomes in certain disease states (reviewed in [140]). To overcome thermal and osmotic stress, probiotics have been suspended in high-osmolarity solutes such as betaine. Additionally, expression cloning of solute-uptake genes for the betaine transporter BetL by Bifidobacterium breve resulted in higher fecal levels of the probiotic in murine stools, probably because of improved survival in the hyperosmotic upper small intestinal lumen. Recently, an E. coli strain was engineered to secrete HIV gp41–hemolysin A hybrid peptides. These peptides block HIV entry into target cells. There are two other studies demonstrating the potential use of designer probiotics in protecting from HIV infection [140].

Another interesting way to magnify probiotic retention and clinical impact is to administer the organism with agents that promote biofilm formation. Recently, Olsen et al. administered L. reuteri grown as a biofilm on the surface of dextranomer microspheres (DM) loaded with mannitol and sucrose. A single dose administered to newborn rat pups was sufficient to reduce the severity of necrotizing enterocolitis [141].

Probiotic products may in some cases replace the probiotics themselves. Metabolites may be identified that can be given instead of or along with live microorganisms. Mechanistic studies have begun to unravel the secrets of probiotic effects. Metabolites mentioned above, including short-chain fatty acids, growth factors, bacteriocins, tryptophan metabolites, and adenosine derivatives, could be beneficial. If the optimal, most potent metabolite were identified for a given disease, it may be possible to achieve the probiotic effect without the inherent risks of live cultures. However, it is possible that sustained luminal levels may not be attained with such an approach or that the effect of the probiotic requires the synthesis of metabolites by microbial consortia.

Finally, the scientific community may begin to refer to probiotics as evidence-based, rather than “alternative” medicine.

Author Contributions: Conceptualization, J.M.R.; Clinical aspects, J.J.A. and J.M.R.; Mechanism section and diagram and formatting/references, Y.L.

Funding: This work was supported by the National Institutes of Health/National Center for Complementary and Integrative Health grant R01AT007083.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. McFarland, L.V. From yaks to yogurt: The history, development, and current use of probiotics. Clin. Infect. Dis. 2015, 60, S85–S90. [CrossRef] [PubMed]
2. Guo, X.; Long, R.; Kreuzer, M.; Ding, L.; Shang, Z.; Zhang, Y.; Yang, Y.; Cui, G. Importance of functional ingredients in yak milk-derived food on health of Tibetan nomads living under high-altitude stress: A review. Crit. Rev. Food Sci. Nutr. 2014, 54, 292–302. [CrossRef] [PubMed]
3. Curtis, R.I. Salted fish products in ancient medicine. *J. Hist. Med. Allied Sci.* 1984, 39, 430–445. [CrossRef] [PubMed]
4. Fisberg, M.; Machado, R. History of yogurt and current patterns of consumption. *Nutr. Rev.* 2015, 73, 4–7. [CrossRef] [PubMed]
5. Gasbarrini, G.; Bonvicini, F.; Gramenzi, A. Probiotics History. *J. Clin. Gastroenterol.* 2016, 50, S116–S119. [CrossRef] [PubMed]
6. Schultz, M. Clinical use of *E. coli* Nissle 1917 in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2008, 14, 1012–1018. [CrossRef] [PubMed]
7. Guarino, A.; Guandalini, S.; Lo, V.A. Probiotics for Prevention and Treatment of Diarrhea. *J. Clin. Gastroenterol.* 2015, 49, S37–S45. [CrossRef] [PubMed]
8. Alfaleh, K.; Bassler, D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. *Cochrane Database Syst. Rev.* 2008, CD005496. [CrossRef]
9. Thomas, J.P.; Raine, T.; Reddy, S.; Belteki, G. Probiotics for the prevention of necrotising enterocolitis in very low-birth-weight infants: A meta-analysis and systematic review. *Acta Paediatr.* 2017, 106, 1729–1741. [CrossRef] [PubMed]
10. Chang, H.Y.; Chen, J.H.; Chang, J.H.; Lin, H.C.; Lin, C.Y.; Peng, C.C. Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis. *PLoS ONE* 2017, 12, e0171579. [CrossRef] [PubMed]
11. Aceti, A.; Gori, D.; Barone, G.; Callegari, M.L.; Di, M.A.; Fantini, M.P.; Indrio, F.; Maggio, L.; Meneghin, F.; Morelli, L.; et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants: Systematic review and meta-analysis. *Ital. J. Pediatr.* 2015, 41, 89–109. [CrossRef] [PubMed]
12. Aceti, A.; Maggio, L.; Beghetti, I.; Gori, D.; Barone, G.; Callegari, M.L.; Fantini, M.P.; Indrio, F.; Meneghin, F.; Morelli, L.; et al. Probiotics Prevent Late-Onset Sepsis in Human Milk-Fed, Very Low Birth Weight Preterm Infants: Systematic Review and Meta-Analysis. *Nutrients* 2017, 9, 904–925. [CrossRef] [PubMed]
13. Khailova, L.; Dvorak, K.; Arganbright, K.M.; Halpern, M.D.; Kinouchi, T.; Yajima, M.; Dvorak, B. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2009, 297, G940–G949. [CrossRef] [PubMed]
14. Good, M.; Sodhi, C.P.; Ozolek, J.A.; Buck, R.H.; Goehring, K.C.; Thomas, D.L.; Vikram, A.; Bibby, K.; Morowitz, M.J.; Firek, B.; et al. Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: Evidence in mice for a role of TLR9. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2014, 306, G1021–G1032. [CrossRef] [PubMed]
15. Hoang, T.K.; He, B.; Wang, T.; Tran, D.Q.; Rhoads, J.M.; Liu, Y. Protective effect of Lactobacillus reuteri DSM 17938 against experimental necrotizing enterocolitis is mediated by Toll-like receptor 2. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2018, 315, G231–G240. [CrossRef] [PubMed]
16. Liu, Y.; Fatheree, N.Y.; Dingle, B.M.; Tran, D.Q.; Rhoads, M. Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. *PLoS ONE* 2013, 8, e56547. [CrossRef] [PubMed]
17. Simren, M.; Palsson, O.S.; Whitehead, W.E. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. *Curr. Gastroenterol. Rep.* 2017, 19, 15–23. [CrossRef] [PubMed]
18. Pozuelo, M.; Panda, S.; Santiago, A.; Mendez, S.; Accarino, A.; Santos, J.; Guarner, F.; Azpiroz, F.; Manichanh, C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. *Sci. Rep.* 2015, 5, 12693–12705. [CrossRef] [PubMed]
19. Ford, A.C.; Quigley, E.M.; Lacy, B.E.; Lembo, A.J.; Saito, Y.A.; Schiller, L.R.; Soffer, E.E.; Spiegel, B.M.; Moayyedi, P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. *Am. J. Gastroenterol.* 2014, 109, 1547–1561. [CrossRef] [PubMed]
20. Zhang, Y.; Li, L.; Guo, C.; Mu, D.; Feng, B.; Zuo, X.; Li, Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. *BMC Gastroenterol.* 2016, 16, 62–73. [CrossRef] [PubMed]
21. Wessel, M.A.; Cobb, J.C.; Jackson, E.B.; Harris, G.S., Jr.; Detwiler, A.C. Paroxysmal fussing in infancy, sometimes called colic. *Pediatrics* 1954, 14, 421–435. [PubMed]
22. de Weerth, C.; Fuentes, S.; Puylaert, P.; de Vos, W.M. Intestinal microbiota of infants with colic: Development and specific signatures. *Pediatrics* 2013, 131, e550–e558. [CrossRef] [PubMed]

23. Rhoads, J.M.; Fatheeree, N.Y.; Norori, J.; Liu, Y.; Lucke, J.F.; Tyson, J.E.; Ferris, M.J. Altered fecal microflora and increased fecal calprotectin in infants with colic. *J. Pediatr.* 2009, 155, 823–828. [CrossRef] [PubMed]

24. Savino, F.; Cordisco, L.; Tarasco, V.; Calabrese, R.; Palumeri, E.; Matteuzzi, D. Molecular identification of coliform bacteria from colicky breastfed infants. *Acta Paediatr.* 2009, 98, 1582–1588. [CrossRef] [PubMed]

25. Taipale, T.; Pienihakkinen, K.; Isolauri, E.; Larsen, C.; Brockmann, E.; Alanen, P.; Jokela, J.; Soderling, E. Molecular identification of intestinal flora by antibiotic aggravates collagen induced arthritis (CIA) in mice. *Clin. Exp. Immunol.* 1993, 92, 1–6. [CrossRef] [PubMed]

26. Harb, T.; Matsuyama, M.; David, M.; Hill, R.J. Infant Colic-What works: A Systematic Review of Interventions for Breast-fed Infants. *J. Pediatr. Gastroenterol. Nutr.* 2016, 62, 668–686. [CrossRef] [PubMed]

27. Sung, V.; D’Amico, F.; Cabana, M.D.; Chau, K.; Koren, G.; Savino, F.; Szajewska, H.; Deshpande, G.; Dupont, C.; Indrio, F.; et al. *Lactobacillus reuteri* to Treat Infant Colic: A Meta-analysis. *Pediatrics* 2018, 141, e20171811. [CrossRef] [PubMed]

28. Xu, M.; Wang, J.; Wang, N.; Sun, F.; Wang, L.; Liu, X.H. The Efficacy and Safety of the Probiotic Bacterium Lactobacillus reuteri DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials. *PLoS ONE* 2015, 10, e0141445. [CrossRef] [PubMed]

29. Maldonado, J.; Canabate, F.; Sempere, L.; Vela, F.; Sanchez, A.R.; Narbona, E.; Lopez-Huertas, E.; Geerlings, A.; Valero, A.D.; Olivares, M.; et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. *J. Pediatr. Gastroenterol. Nutr.* 2012, 54, 55–61. [CrossRef] [PubMed]

30. Rautava, S.; Salminen, S.; Isolauri, E. Specific probiotics in reducing the risk of acute infections in infancy—a randomised, double-blind, placebo-controlled study. *Br. J. Nutr.* 2009, 101, 1722–1726. [CrossRef] [PubMed]

31. Smith, T.J.; Rigassio-Radler, D.; Denmark, R.; Haley, T.; Touger-Decker, R. Effect of *Lactobacillus rhamnosus* LGG(R) and *Bifidobacterium animalis* subsp. lactis BB-12(R) on health-related quality of life in college students affected by upper respiratory infections. *Br. J. Nutr.* 2013, 109, 1999–2007. [CrossRef] [PubMed]

32. Taipale, T.; Pienihakkinen, K.; Isolauri, E.; Larsen, C.; Brockmann, E.; Alanen, P.; Jokela, J.; Soderling, E. *Bifidobacterium animalis* subsp. lactis BB-12 in reducing the risk of infections in infancy. *Br. J. Nutr.* 2011, 105, 409–416. [CrossRef] [PubMed]

33. Nocerino, R.; Paparo, L.; Terrin, G.; Pezzella, V.; Amoroso, A.; Cosenza, L.; Cecere, G.; De, M.G.; Micillo, M.; Albano, F.; et al. Cow’s milk and rice fermented with *Lactobacillus paracasei* CBA L74 prevent infectious diseases in children: A randomized controlled trial. *Clin. Nutr.* 2017, 36, 118–125. [CrossRef] [PubMed]

34. Villena, J.; Barbieri, N.; Salva, S.; Herrera, M.; Alvarez, S. Enhanced immune response to pneumococcal infection in malnourished mice nasally treated with heat-killed Lactobacillus casei. *Microbiol. Immunol.* 2009, 53, 636–646. [CrossRef] [PubMed]

35. Ishizaki, A.; Bi, X.; Nguyen, L.V.; Matsuda, K.; Pham, H.V.; Phan, C.T.T.; Khu, D.T.K.; Ichimura, H. Effects of Short-Term Probiotic Ingestion on Immune Profiles and Microbial Translocation among HIV-1-Infected Vietnamese Children. *Int. J. Mol. Sci.* 2017, 18, E2185. [CrossRef] [PubMed]

36. McCulloch, J.; Lydyard, P.M.; Rook, G.A. Rheumatoid arthritis: How well do the theories fit the evidence? *Clin. Exp. Immunol.* 1993, 92, 1–6. [CrossRef] [PubMed]

37. Mohammed, A.T.; Khattab, M.; Ahmed, A.M.; Turk, T.; Sakr, N.; Khalil, M.; Abdelhalim, M.; Sawaf, B.; Hirayama, K.; Huy, N.T. The therapeutic effect of probiotics on rheumatoid arthritis: A systematic review and meta-analysis of randomized control trials. *Clin. Rheumatol.* 2017, 36, 2697–2707. [CrossRef] [PubMed]

38. de Oliveira, G.L.V.; Leite, A.Z.; Higuchi, B.S.; Gonzaara, M.I.; Mariano, V.S. Intestinal dysbiosis and probiotic applications in autoimmune diseases. *Immunology* 2017, 152, 1–12. [CrossRef] [PubMed]

39. Eerola, E.; Mottonen, T.; Hannonen, P.; Luukkainen, R.; Kantola, I.; Vuori, K.; Tuominen, J.; Toivanen, P. Intestinal flora in early rheumatoid arthritis. *Br. J. Rheumatol.* 1994, 33, 1030–1038. [CrossRef] [PubMed]

40. Brusca, S.B.; Abramson, S.B.; Scher, J.U. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. *Curr. Opin. Rheumatol.* 2014, 26, 101–107. [CrossRef] [PubMed]

41. Dorozynska, I.; Majewska-Szczepeanik, M.; Marcinska, K.; Szczepeanik, M. Partial depletion of natural gut flora by antibiotic aggravates collagen induced arthritis (CIA) in mice. *Pharmacol. Rep.* 2014, 66, 250–255. [CrossRef] [PubMed]
42. Hataoka, K.; Martio, J.; Korpela, M.; Herranen, M.; Poussa, T.; Laasanen, T.; Saxelin, M.; Vapaatalo, H.; Moilanen, E.; Korpela, R. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis—A pilot study. *Scand. J. Rheumatol.* 2003, 32, 211–215. [CrossRef] [PubMed]
43. Zamani, B.; Golkar, H.R.; Farshbaf, S.; Emadi-Baygi, M.; Tajabadi-Ebrahimi, M.; Jafari, P.; Akhavan, R.; Taghizadeh, M.; Memarzadeh, M.R.; Asemi, Z. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. *Int. J. Rheum. Dis.* 2016, 19, 869–879. [CrossRef] [PubMed]
44. Chen, J.; Wright, K.; Davis, J.M.; Jerald, P.; Marietta, E.V.; Murray, J.; Nelson, H.; Matteson, E.L.; Taneja, V. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med.* 2016, 8, 43–57. [CrossRef] [PubMed]
45. Alipour, B.; Homayouni-Rad, A.; Vaghef-Mehrabany, E.; Sharif, S.K.; Vaghef-Mehrabany, L.; Asghari-Jafarabadi, M.; Nakhjavani, M.R.; Mohtadi-Nia, J. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: A randomized double-blind clinical trial. *Int. J. Rheum. Dis.* 2014, 17, 519–527. [CrossRef] [PubMed]
46. Liu, X.; Zou, Q.; Zeng, B.; Fang, Y.; Wei, H. Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. *Curr. Microbiol.* 2013, 67, 170–176. [CrossRef] [PubMed]
47. Rahman, A.; Isenberg, D.A. Systemic lupus erythematosus. *N. Engl. J. Med.* 2008, 358, 929–939. [CrossRef] [PubMed]
48. Stevens, K.M. The Aetiology of Systemic Lupus Erythematosus. *Lancet* 1964, 2, 506–508. [CrossRef]
49. Lopez, P.; de, P.B.; Rodriguez-Carro, J.; Hevia, A.; Sanchez, B.; Margolles, A.; Suarez, A. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients. *Sci. Rep.* 2016, 6, 24072. [CrossRef] [PubMed]
50. Esmaeili, S.A.; Mahmoudi, M.; Momtazi, A.A.; Sahebkar, A.; Doulabi, H.; Rastin, M. Tolerogenic probiotics: Potential immunoregulators in Systemic Lupus Erythematosus. *J. Cell. Physiol.* 2017, 232, 1994–2007. [CrossRef] [PubMed]
51. Mu, Q.; Zhang, H.; Liao, X.; Lin, K.; Liu, H.; Edwards, M.R.; Ahmed, S.A.; Yuan, R.; Li, L.; Cecere, T.E.; et al. Control of lupus nephritis by changes of gut microbiota. *Microbiome* 2017, 5, 73. [CrossRef] [PubMed]
52. Tzang, B.S.; Liu, C.H.; Hsu, K.C.; Chen, Y.H.; Huang, C.Y.; Hsu, T.C. Effects of oral Lactobacillus administration on antioxidant activities and CD4+CD25+forkhead box P3 (FoxP3)+ T cells in NZB/W F1 mice. *Br. J. Nutr.* 2017, 118, 333–342. [CrossRef] [PubMed]
53. Esmaeili, S.A.; Mahmoudi, M.; Rezaieyazdi, Z.; Sahebkar, M.; Tabasi, N.; Sahebkar, A.; Rastin, M. Generation of tolerogenic dendritic cells using Lactobacillus rhamnosus and Lactobacillus delbrueckii as tolerogenic probiotics. *J. Cell. Biochem.* 2018, 119, 7865–7872. [CrossRef] [PubMed]
54. Frech, T.M.; Khanna, D.; Maranian, P.; Frech, E.J.; Sawitzke, A.D.; Murthaugh, M.A. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. *Clin. Exp. Rheumatol.* 2011, 29, S22–S25. [PubMed]
55. Derwa, Y.; Gracie, D.J.; Hamlin, P.F.; Ford, A.C. Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 2017, 46, 389–400. [CrossRef] [PubMed]
56. Shen, J.; Zuo, Z.X.; Mao, A.P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: Meta-analysis of randomized controlled trials. *Inflamm. Bowel Dis.* 2014, 20, 21–35. [CrossRef] [PubMed]
57. Roehr, M.; Narasimhulu, C.A.; Sharma, D.; Doomra, M.; Riad, A.; Naser, S.; Parthasarathy, S. Inflammatory Diseases of the Gut. *J. Med. Food* 2018, 21, 113–126. [CrossRef] [PubMed]
58. Shen, J.; Quan, Y.S.; Yang, Z.Y.; Wu, S.; Luo, W.W.; Tan, B.; Wang, X.Y. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. *World J. Gastroenterol.* 2018, 24, 5–14. [CrossRef] [PubMed]
59. Ganji-Arjenaki, M.; Rafieian-Kopaei, M. Probiotics are a good choice in remission of inflammatory bowel disease. *Microbiome* 2013, 170–176. [PubMed]
60. Goverman, J. Autoimmune T cell responses in the central nervous system. *Nat. Rev. Immunol.* 2009, 9, 393–407. [CrossRef] [PubMed]
61. Nylander, A.; Hafler, D.A. Multiple sclerosis. *J. Clin. Investig.* 2012, 122, 1180–1188. [CrossRef] [PubMed]
62. McFarland, H.F.; Martin, R. Multiple sclerosis: A complicated picture of autoimmunity. *Nat. Immunol.* 2007, 8, 913–919. [CrossRef] [PubMed]
63. Berer, K.; Mues, M.; Koutrolos, M.; Rasbi, Z.A.; Boziki, M.; Johner, C.; Wekerle, H.; Krishnamoorthy, G. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. *Nature* 2011, 479, 538–541. [CrossRef] [PubMed]

64. Chen, J.; Chia, N.; Kalari, K.R.; Yao, J.Z.; Novotna, M.; Soldan, M.M.; Luckey, D.H.; Marietta, E.V.; Jeraldo, P.R.; Chen, X.; et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Sci. Rep.* 2016, 6, 28484. [CrossRef] [PubMed]

65. Jangi, S.; Gandhi, R.; Cox, L.M.; Li, N.; von, G.F.; Yan, R.; Patel, B.; Mazzola, M.A.; Liu, S.; Glanz, B.L.; et al. Alterations of the human gut microbiome in multiple sclerosis. *Nat. Commun.* 2016, 7, 12015. [CrossRef]

66. Newland, P.K.; Heitkemper, M.; Zhou, Y. The Emerging Role of the Gut Microbiome in Adult Patients with Multiple Sclerosis. *J. Neurosci. Nurs.* 2016, 48, 358–364. [CrossRef] [PubMed]

67. Ochoa-Reparaz, J.; Mielcarz, D.W.; Ditrio, L.E.; Burroughs, A.R.; Foureau, D.M.; Haque-Begum, S.; Kasper, L.H. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. *J. Immunol.* 2009, 183, 6041–6050. [CrossRef] [PubMed]

68. Yokote, H.; Miyake, S.; Croxford, J.L.; Oki, S.; Mizusawa, H.; Yamamura, T. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. *Am. J. Pathol.* 2008, 173, 1714–1723. [CrossRef] [PubMed]

69. He, B.; Hoang, T.K.; Tian, X.; Taylor, C.M.; Blanchard, E.; Luo, M.; Bhattacharjee, M.B.; Lindsey, J.M.; Tran, D.Q.; J Marc Rhoads, J.M.; et al. Lactobacillus reuteri reduces the severity of experimental autoimmune encephalomyelitis in mice by modulating gut microbiota. *Front Immunol.* under review.

70. Kouchaki, E.; Tamtaji, O.R.; Salami, M.; Bahmani, F.; Daneshvar, K.R.; Akbari, E.; Tajabadi-Ebrahimi, M.; Jafari, P.; Asemi, Z. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. *Clin. Nutr.* 2017, 36, 1245–1249. [CrossRef] [PubMed]

71. Pessione, E. Lactic acid bacteria contribution to gut microbiota complexity: Lights and shadows. *Front. Cell. Infect. Microbiol.* 2012, 2, 86. [CrossRef] [PubMed]

72. Louis, P.; Flint, H.J. Formation of propionate and butyrate by the human colonic microbiota. *Environ. Microbiol.* 2017, 19, 29–41. [CrossRef] [PubMed]

73. Macfarlane, S.; Macfarlane, G.T. Regulation of short-chain fatty acid production. *Proc. Nutr. Soc.* 2003, 62, 67–72. [CrossRef] [PubMed]

74. Sivieri, K.; Morales, M.L.; Adorno, M.A.; Sakamoto, I.K.; Saad, S.M.; Rossi, E.A. Lactobacillus acidophilus CRL 1014 improved “gut health” in the SHIME reactor. *BMC Gastroenterol.* 2013, 13, 100. [CrossRef] [PubMed]

75. LeBlanc, J.G.; Chain, F.; Martin, R.; Bermudez-Humaran, L.G.; Courau, S.; Langella, P. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. *Microb. Cell Fact.* 2017, 16, 79. [CrossRef] [PubMed]

76. Canani, R.B.; Costanzo, M.D.; Leone, L.; Calignano, A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol.* 2011, 17, 1519–1528. [CrossRef] [PubMed]

77. Keku, T.O.; Dulal, S.; Deveaux, A.; Jovov, B.; Han, X. The gastrointestinal microbiota and colorectal cancer. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2015, 308, G351–G363. [CrossRef] [PubMed]

78. Dass, N.B.; John, A.K.; Bassil, A.K.; Crumbley, C.W.; Shehee, W.R.; Maurio, F.P.; Taylor, C.M.; Sanger, G.J. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. *Neurogastroenterol. Motil.* 2007, 19, 66–74. [CrossRef] [PubMed]
82. Kespohl, M.; Vachharajani, N.; Luu, M.; Harb, H.; Pautz, S.; Wolff, S.; Sillner, N.; Walker, A.; Schmitt-Kopplin, P.; Boettger, T.; et al. The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4(+) T Cells. *Front Immunol.* 2017, 8, 1036. [CrossRef] [PubMed]

83. Bianchetti, D.G.A.M.; Amelio, G.S.; Lava, S.A.G.; Bianchetti, M.G.; Simonetti, G.D.; Agostoni, C.; Fossali, E.F.; Milani, G.P. D-lactic acidosis in humans: Systematic literature review. *Pediatr. Nephrol.* 2018, 33, 673–681. [CrossRef] [PubMed]

84. Cahova, M.; Bratova, M.; Wohl, P. Parenteral Nutrition-Associated Liver Disease: The Role of the Gut Microbiota. *Nutrients* 2017, 9, 987. [CrossRef] [PubMed]

85. Mayeur, C.; Gratadoux, J.J.; Bridonneau, C.; Chegdani, F.; Larroque, B.; Kapel, N.; Corcos, O.; Thomas, M.; Joly, F. Faecal D/L lactate ratio is a metabolic signature of microbiota imbalance in patients with short bowel syndrome. *PLoS ONE* 2013, 8, e54335. [CrossRef] [PubMed]

86. Hubbard, T.D.; Murray, I.A.; Bisson, W.H.; Lahoti, T.S.; Gowda, K.; Amin, S.G.; Patterson, A.D.; Perdew, G.H. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. *Sci. Rep.* 2015, 5, 12689. [CrossRef] [PubMed]

87. Gao, J.; Xu, K.; Liu, H.; Liu, G.; Bai, M.; Peng, C.; Li, T.; Yin, Y. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. *Front. Cell. Infect. Microbiol.* 2018, 8, 13. [CrossRef] [PubMed]

88. Korecka, A.; Dona, A.; Lahiri, S.; Tett, A.J.; Al-Asmakh, M.; Braniste, V.; D’Arienzo, R.; Abbaspour, A.; Reichardt, N.; Fuji-Kuriyama, Y.; et al. Bidirectional communication between the Aryl hydrocarbon Receptor (AhR) and the microbiome tunes host metabolism. *NPJ Biofilms Microbiomes* 2016, 2, 16014. [CrossRef] [PubMed]

89. Benson, J.M.; Shepherd, D.M. Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn’s disease. *Toxicol. Sci.* 2011, 120, 68–78. [CrossRef] [PubMed]

90. Sutter, C.H.; Bodreddigari, S.; Campion, C.; Wible, R.S.; Sutter, T.R. 2,3,7,8-Tetrachlorodibenzo-p-dioxin increases the expression of genes in the human epidermal differentiation complex and accelerates epidermal barrier formation. *Toxicol. Sci.* 2011, 124, 128–137. [CrossRef] [PubMed]

91. Shi, L.Z.; Faith, N.G.; Nakayama, Y.; Suresh, M.; Steinberg, H.; Czuprynski, C.J. The aryl hydrocarbon receptor is required for optimal resistance to Listeria monocytogenes infection in mice. *J. Immunol.* 2007, 179, 6952–6962. [CrossRef] [PubMed]

92. Behnsen, J.; Jellbauer, S.; Wong, C.P.; Edwards, R.A.; George, M.D.; Ouyang, W.; Raffatellu, M. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. *Immunity* 2014, 40, 262–273. [CrossRef] [PubMed]

93. Venkatesh, M.; Mukherjee, S.; Wang, H.; Li, H.; Sun, K.; Benech, A.P.; Qiu, Z.; Maher, L.; Redinbo, M.R.; Phillips, R.S.; et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. *Immunity* 2014, 41, 296–310. [CrossRef] [PubMed]

94. Desbonnet, L.; Garrett, L.; Clarke, G.; Bienenstock, J.; Dinan, T.G. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. *J. Psychiatr. Res.* 2008, 43, 164–174. [CrossRef] [PubMed]

95. Zelante, T.; Iannitti, R.G.; Cunha, C.; De, I.A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D’Angelo, C.; Massi-Benedetti, C.; Fallarino, F.; et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* 2013, 39, 372–385. [CrossRef] [PubMed]

96. Heldin, C.H.; Moustakas, A. Role of Smads in TGFbeta signaling. *Cell Tissue Res.* 2012, 347, 21–36. [CrossRef] [PubMed]

97. Tran, D.Q. TGF-beta: The sword, the wand, and the shield of FOXP3(+) regulatory T cells. *J. Mol. Cell Biol.* 2012, 4, 29–37. [CrossRef] [PubMed]

98. Liu, Y.; Tran, D.Q.; Fatheree, N.Y.; Marc, R.J. Lactobacillus reuteri DSM 17938 differentially modulates effector memory T cells and Foxp3+ regulatory T cells in a mouse model of necrotizing enterocolitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2014, 307, G177–G186. [CrossRef] [PubMed]

99. Sakai, F.; Hosoya, T.; Ono-Ohmachi, A.; Ukibe, K.; Ogawa, A.; Moriya, T.; Kadooka, Y.; Shiozaki, T.; Nakagawa, H.; Nakayama, Y.; et al. Lactobacillus gasseri SBT2055 induces TGF-beta expression in dendritic cells and activates TLR2 signal to produce IgA in the small intestine. *PLoS ONE* 2014, 9, e105370. [CrossRef] [PubMed]
100. Barletta, B.; Rossi, G.; Schiavi, E.; Butteroni, C.; Corinti, S.; Boirivant, M.; Di, F.G. Probiotic VSL#3-induced TGF-beta ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa. *Mol. Nutr. Food Res.* 2013, 57, 2223–2244. [PubMed]

101. Fujii, T.; Ohtsuka, Y.; Lee, T.; Kudo, T.; Shoji, H.; Sato, H.; Nagata, S.; Shimizu, T.; Yamashiro, Y. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. *J. Pediatr. Gastroenterol. Nutr.* 2006, 43, 83–88. [CrossRef] [PubMed]

102. Huang, I.F.; Lin, I.C.; Liu, P.F.; Cheng, M.F.; Liu, Y.C.; Hsieh, Y.D.; Chen, J.J.; Chen, C.L.; Chang, H.W.; Shu, C.W. Lactobacillus acidophilus attenuates Salmonella-induced intestinal inflammation via TGF-beta signaling. *BMC Microbiol.* 2015, 15, 203. [CrossRef] [PubMed]

103. He, B.; Hoang, T.K.; Wang, T.; Ferris, M.; Taylor, C.M.; Tian, X.; Luo, M.; Tran, D.Q.; Zhou, J.; Tavejian, N.; et al. Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency-induced autoimmunity via adenosine A2A receptors. *J. Exp. Med.* 2017, 214, 107–123. [CrossRef] [PubMed]

104. He, B.; Hoang, T.K.; Tran, D.Q.; Rhoads, J.M.; Liu, Y. Adenosine A2A Receptor Deletion Blocks the Beneficial Effects of Lactobacillus reuteri in Regulatory T-Deficient Scurfy Mice. *Front. Immunol.* 2017, 8, 1680. [CrossRef] [PubMed]

105. Hannibal, M.C.; Torgerson, T. IPEX Syndrome. Available online: http://www.ncbi.nlm.nih.gov/books/NBK11118/ (accessed on 12 October 2018).

106. Frei, R.; Ferstl, R.; Konieczna, P.; Ziegler, M.; Simon, T.; Rugeles, T.M.; Mailand, S.; Watanabe, T.; Lauener, R.; Akdis, C.A.; et al. Histamine receptor 2 modifies dendritic cell responses to microbial ligands. *J. Allergy Clin. Immunol.* 2013, 132, 194–204. [CrossRef] [PubMed]

107. Ganesh, B.P.; Hall, A.; Ayyaswamy, S.; Nelson, J.W.; Fultz, R.; Major, A.; Haag, A.; Esparza, M.; Lugo, M.; Venable, S.; et al. Diacylglycerol kinase synthesized by commensal Lactobacillus reuteri diminishes protein kinase C phosphorylation and histamine-mediated signaling in the mammalian intestinal epithelium. *Mucosal. Immunol.* 2018, 11, 380. [CrossRef] [PubMed]

108. Ferstl, R.; Frei, R.; Schiavi, E.; Konieczna, P.; Barcik, W.; Ziegler, M.; Lauener, R.P.; Chassard, C.; Lacroix, C.; Akdis, C.A.; et al. Histamine receptor 2 is a key influence in immune responses to intestinal histamine-secreting microbes. *J. Allergy Clin. Immunol.* 2014, 134, 744–746. [CrossRef] [PubMed]

109. Thomas, C.M.; Hong, T.; van Pijkeren, J.P.; Hemarajata, P.; Trinh, D.V.; Hu, W.; Britton, R.A.; Kalkum, M.; Versalovic, J. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. *PLoS ONE* 2012, 7, e31951. [CrossRef] [PubMed]

110. Gao, C.; Major, A.; Rendon, D.; Lugo, M.; Jackson, V.; Shi, Z.; Mori-Akiyama, Y.; Versalovic, J. Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic Lactobacillus reuteri. *MBio.* 2015, 6, e01358–e01415. [CrossRef] [PubMed]

111. Gao, C.; Ganesh, B.P.; Shi, Z.; Shah, R.R.; Fultz, R.; Major, A.; Venable, S.; Lugo, M.; Hoch, K.; Chen, X.; et al. Gut Microbe-Mediated Suppression of Inflammation-Associated Colon Carcinogenesis by Luminal Histamine Production. *Am. J. Pathol.* 2017, 187, 2323–2336. [CrossRef] [PubMed]

112. NIH/National Center for Complementary and Integrative Health. Probiotics: In Depth. Available online: http://nccih.nih.gov/health/probiotics/introduction.htm (accessed on 10 September 2018).

113. CDC/Centers for Disease Control and Prevention. Fatal Gastrointestinal Mucormycosis in an Infant Following Use of Contaminated ABC Dophilus Powder from Solgar Inc. Available online: http://www.cdc.gov/fungal/outbreaks/rhizopus-investigation.html (accessed on 10 September 2018).

114. Sun, J.; Marwah, G.; Westgarth, M.; Buys, N.; Ellwood, D.; Gray, P.H. Effects of Probiotics on Necrotizing Enterocolitis, Sepsis, Intraventricular Hemorrhage, Mortality, Length of Hospital Stay, and Weight Gain in Very Preterm Infants: A Meta-Analysis. *Adv. Nutr.* 2017, 8, 749–763. [CrossRef] [PubMed]

115. Zhang, G.Q.; Hu, H.J.; Liu, C.Y.; Shakya, S.; Li, Z.Y. Probiotics for Preventing Late-Onset Sepsis in Very Preterm Neonates: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine (Baltimore)* 2016, 95, e2581. [CrossRef] [PubMed]

116. Arumugam, S.; Lau, C.S.; Chamberlain, R.S. Probiotics and Synbiotics Decrease Postoperative Sepsis in Elective Gastrointestinal Surgical Patients: A Meta-Analysis. *J. Gastrointest. Surg.* 2016, 20, 1123–1131. [CrossRef] [PubMed]

117. Sender, R.; Fuchs, S.; Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol.* 2016, 14, e1002533. [CrossRef] [PubMed]
118. Lim, J.Y.; Yoon, J.; Hovde, C.J. A brief overview of Escherichia coli O157:H7 and its plasmid O157. *J. Microbiol. Biotechnol.* **2010**, *20*, 5–14. [PubMed]

119. Larsen, C.N.; Nielsen, S.; Kaestel, P.; Brockmann, E.; Bennedsen, M.; Christensen, H.R.; Eskesen, D.C.; Jacobsen, B.L.; Michaelsen, K.F. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. *Eur. J. Clin. Nutr.* **2006**, *60*, 1284–1293. [CrossRef] [PubMed]

120. Dommels, Y.E.; Kemperman, R.A.; Zebregs, Y.E.; Draaisma, R.B.; Jol, A.; Wolvers, D.A.; Vaughan, E.E.; Albers, R. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. *Appl. Environ. Microbiol.* **2009**, *75*, 6198–6204. [CrossRef] [PubMed]

121. Sonisepp, E.; Kals, J.; Kullisaar, T.; Mandar, R.; Hutt, P.; Zilmer, M.; Mikelsaar, M. Evaluation of the efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. *Gut* **2010**, *59*, 325–332. [CrossRef] [PubMed]

122. Athalye-Jape, G.; Rao, S.; Patole, S. Effects of probiotics on experimental necrotizing enterocolitis: A systematic review and meta-analysis. *Pediatr. Res.* **2018**, *83*, 16–22. [CrossRef] [PubMed]

123. Schouten, J.N.; Van der Ende, M.E.; Koeter, T.; Rossing, H.H.; Komuta, M.; Verheij, J.; van der Valk, M.; Hansen, B.E.; Janssen, H.L. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. *Aliment. Pharmacol. Ther.* **2012**, *36*, 875–885. [CrossRef] [PubMed]

124. Mangalat, N.; Liu, Y.; Ferris, M.J.; Van Arsdall, M.R.; Chen, Z.; Rahbar, M.H.; Gleason, W.A.; Norori, J.; Tran, D.Q.; et al. Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: Results from a randomized masked trial. *PLoS ONE* **2012**, *7*, e43910. [CrossRef] [PubMed]

125. Fatheree, N.Y.; Liu, Y.; Ferris, M.; Van, A.M.; McMurtry, V.; Zozaya, M.; Cai, C.; Rahbar, M.H.; Hessabi, M.; Vu, T.; et al. Hypoallergenic formula with Lactobacillus rhamnosus GG for babies with colic: A pilot study of recruitment, retention, and fecal biomarkers. *World J. Gastrointest. Pathophysiol.* **2016**, *7*, 160–170. [CrossRef] [PubMed]

126. Sedgwick, P.; Marston, L. How to read a funnel plot in a meta-analysis. *BMJ* **2015**, *351*, h4718. [CrossRef] [PubMed]

127. Athalye-Jape, G.; Rao, S.; Patole, S. Effects of probiotics on experimental necrotizing enterocolitis: A systematic review and meta-analysis. *Pediatr. Res.* **2018**, *83*, 16–22. [CrossRef] [PubMed]

128. Moayyedi, P.; Ford, A.C.; Talley, N.J.; Cremonini, F.; Foxx-Orenstein, A.E.; Brandt, L.J.; Quigley, E.M. The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. *Gut* **2010**, *59*, 325–332. [CrossRef] [PubMed]

129. Si, X.B.; Lan, Y.; Qiao, L. A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori. *Zhonghua Nei Ke Za Zhi* **2010**, *56*, 752–759. (In Chinese) [PubMed]

130. Gutierrez-Castrellon, P.; Indrio, F.; Polio-Galvis, A.; Jimenez-Gutierrez, C.; Jimenez-Escobar, I.; Lopez-Velazquez, G. Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: Systematic review with network meta-analysis. *Medicine (Baltimore)* **2017**, *96*, e9375. [CrossRef] [PubMed]

131. Salari, P.; Nikfar, S.; Abdollahi, M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. *Inflamm. Allergy Drug Targets* **2012**, *11*, 3–14. [CrossRef] [PubMed]

132. Ladas, E.J.; Bhatia, M.; Chen, L.; Sandler, E.; Petrovic, A.; Berman, D.M.; Hamblin, F.; Gates, M.; Hawks, R.; Sung, L.; et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. *Bone Marrow Transplant.* **2016**, *51*, 262–266. [CrossRef] [PubMed]

133. Liu, Z.H.; Huang, M.J.; Zhang, X.W.; Wang, L.; Huang, N.Q.; Peng, H.; Lan, P.; Peng, J.S.; Yang, Z.; Xia, Y.; et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: A double-center and double-blind randomized clinical trial. *Am. J. Clin. Nutr.* **2013**, *97*, 117–126. [CrossRef] [PubMed]

134. Stiksrud, B.; Nowak, P.; Nwosu, F.C.; Kvale, D.; Thalme, A.; Sonnerborg, A.; Ueland, P.M.; Holm, K.; Birkeland, S.E.; Dahm, A.E.; et al. Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART. *J. Acquir. Immune. Defic. Syndr.* **2015**, *70*, 329–337. [CrossRef] [PubMed]
135. Tan, C.K.; Said, S.; Rajandram, R.; Wang, Z.; Roslani, A.C.; Chin, K.F. Pre-surgical Administration of Microbial Cell Preparation in Colorectal Cancer Patients: A Randomized Controlled Trial. *World J. Surg.* 2016, 40, 1985–1992. [CrossRef] [PubMed]

136. Van den Nieuwboer, M.; Brummer, R.J.; Guarner, F.; Morelli, L.; Cabana, M.; Claasen, E. The administration of probiotics and synbiotics in immune compromised adults: Is it safe? *Benef. Microbes* 2015, 6, 3–17. [CrossRef] [PubMed]

137. Guarino, A.; Lo, V.A.; Dias, J.A.; Berkley, J.A.; Boey, C.; Bruzzese, D.; Cohen, M.B.; Cruchet, S.; Liguoro, I.; Salazar-Lindo, E.; et al. Universal recommendations for the management of acute diarrhea in non-malnourished children. *J. Pediatr. Gastroenterol. Nutr.* 2018. [CrossRef] [PubMed]

138. Parker, M.W.; Schaffzin, J.K.; Lo, V.A.; Yau, C.; Vonderhaar, K.; Guiot, A.; Brinkman, W.B.; White, C.M.; Simmons, J.M.; Gerhardt, W.E.; et al. Rapid adoption of Lactobacillus rhamnosus GG for acute gastroenteritis. *Pediatrics* 2013, 131, S96–S102. [CrossRef] [PubMed]

139. Yi, S.H.; Jernigan, J.A.; McDonald, L.C. Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. *Am. J. Infect. Control* 2016, 44, 548–553. [CrossRef] [PubMed]

140. Sleator, R.D. Designer probiotics: Development and applications in gastrointestinal health. *World J. Gastrointest. Pathophysiol.* 2015, 6, 73–78. [CrossRef] [PubMed]

141. Olson, J.K.; Navarro, J.B.; Allen, J.M.; McCulloh, C.J.; Mashburn-Warren, L.; Wang, Y.; Varaljay, V.A.; Bailey, M.T.; Goodman, S.D.; Besner, G.E. An enhanced Lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2018, 315, G408–G419. [CrossRef] [PubMed]